Type 2 Diabetes Clinical Trial
Official title:
Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria
The purpose of this study is to determine whether intensified multifactorial intervention comprising both behaviour modification and polypharmacy can reduce the risk for late diabetic complications compared to standard treatment in patients with type 2 diabetes and microalbuminuria.
The overall description of the Steno-2 Study is stated in four protocols approved by the
regulatory authorities in Denmark. The protocol identification numbers are KA 92071gm (4
years intervention ), KA-99035g (8 years intervention ), KA-99035-GS (13 years follow-up
since intervention start) and H-KA-99035-GS (21 year follow-up since intervention start).
The aim of the study was to determine whether intensified multifactorial intervention
comprising both behaviour modification and polypharmacy can reduce the risk for late diabetic
complications compared to standard treatment in patients with type 2 diabetes and
microalbuminuria. The primary end point after four years of intervention was to progression
to diabetic nephropathy with other microvascular complications as secondary end points. The
primary end point after eight years of intervention was a composite CVD endpoint with
microvascular complications as secondary end points.
The interventional part of the study was ended in December 2001 after a total of eight years
of intervention. From that time on, all patients were followed in a post-trial study. Also,
during post-trial period all patients in both original treatment arms received similar
treatment resembling the treatment given in the original intensive arm of the study. The aim
of the post-trial follow-up was to investigate the effect of intensified multifactorial
intervention on i) mortality and ii) years of life gained, respectively, with such an
interventional approach.
Endpoints in the two parts of the post-trial follow-up:
Part one at 13 years since start of intervention:
Primary endpoint: Total mortality. Secondary endpoints: Cardiovascular endpoints as defined
previously; Microvascular disease.
Part two at 21 years since start of intervention:
Primary endpoint: Difference in median time to 50% mortality in each of the two original
treatment groups Secondary endpoints: Cardiovascular endpoints as defined previously;
Recurrent cardiovascular events; Microvascular disease.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |